<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34383907</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>28</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1554-6578</ISSN><JournalIssue CitedMedium="Internet"><Volume>80</Volume><Issue>8</Issue><PubDate><Year>2021</Year><Month>Sep</Month><Day>10</Day></PubDate></JournalIssue><Title>Journal of neuropathology and experimental neurology</Title><ISOAbbreviation>J Neuropathol Exp Neurol</ISOAbbreviation></Journal><ArticleTitle>Fast Progression in Amyotrophic Lateral Sclerosis Is Associated With Greater TDP-43 Burden in Spinal Cord.</ArticleTitle><Pagination><StartPage>754</StartPage><EndPage>763</EndPage><MedlinePgn>754-763</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/jnen/nlab061</ELocationID><Abstract><AbstractText>Upper and lower motor neuron pathologies are critical to the autopsy diagnosis of amyotrophic lateral sclerosis (ALS). Further investigation is needed to determine how the relative burden of these pathologies affects the disease course. We performed a blinded, retrospective study of 38 ALS patients, examining the association between pathologic measures in motor cortex, hypoglossal nucleus, and lumbar cord with clinical data, including progression rate and disease duration, site of symptom onset, and upper and lower motor neuron signs. The most critical finding in our study was that TAR DNA-binding protein 43&#x2009;kDa (TDP-43) pathologic burden in lumbar cord and hypoglossal nucleus was significantly associated with a faster progression rate with reduced survival (p&#x2009;&lt;&#x2009;0.02). There was no correlation between TDP-43 burden and the severity of cell loss, and no significant clinical associations were identified for motor cortex TDP-43 burden or severity of cell loss in motor cortex. C9orf72 expansion was associated with shorter disease duration (p&#x2009;&lt;&#x2009;0.001) but was not significantly associated with pathologic measures in these regions. The association between lower motor neuron TDP-43 burden and fast progression with reduced survival in ALS provides further support for the study of TDP-43 as a disease biomarker.</AbstractText><CopyrightInformation>&#xa9; 2021 American Association of Neuropathologists, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cathcart</LastName><ForeName>Sahara J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>From the Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Nebraska Medical Center, Omaha, Nebraska, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Appel</LastName><ForeName>Stanley H</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Stanley H. Appel Department of Neurology, Houston Methodist Hospital, Houston, Texas, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Academic Medicine at the Houston Methodist Research Institute, Houston Methodist Hospital, Houston, Texas, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Houston Methodist Neurological Institute, Houston Methodist Hospital, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peterson</LastName><ForeName>Leif E</ForeName><Initials>LE</Initials><AffiliationInfo><Affiliation>NXG Logic, LLC, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greene</LastName><ForeName>Ericka P</ForeName><Initials>EP</Initials><AffiliationInfo><Affiliation>Stanley H. Appel Department of Neurology, Houston Methodist Hospital, Houston, Texas, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Academic Medicine at the Houston Methodist Research Institute, Houston Methodist Hospital, Houston, Texas, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Houston Methodist Neurological Institute, Houston Methodist Hospital, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Powell</LastName><ForeName>Suzanne Z</ForeName><Initials>SZ</Initials><AffiliationInfo><Affiliation>From the Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Houston Methodist Neurological Institute, Houston Methodist Hospital, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arumanayagam</LastName><ForeName>Anithachristy S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>From the Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rivera</LastName><ForeName>Andreana L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Institute of Academic Medicine at the Houston Methodist Research Institute, Houston Methodist Hospital, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cykowski</LastName><ForeName>Matthew D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>From the Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stanley H. Appel Department of Neurology, Houston Methodist Hospital, Houston, Texas, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Academic Medicine at the Houston Methodist Research Institute, Houston Methodist Hospital, Houston, Texas, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RF1 NS118584</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neuropathol Exp Neurol</MedlineTA><NlmUniqueID>2985192R</NlmUniqueID><ISSNLinking>0022-3069</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009044" MajorTopicYN="N">Motor Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Lower motor neuron</Keyword><Keyword MajorTopicYN="N">Motor cortex</Keyword><Keyword MajorTopicYN="N">Progression rate</Keyword><Keyword MajorTopicYN="N">Spinal cord</Keyword><Keyword MajorTopicYN="N">TAR DNA-binding protein 43 kDa (TDP-43)</Keyword><Keyword MajorTopicYN="N">Upper motor neuron</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>8</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>8</Month><Day>12</Day><Hour>17</Hour><Minute>31</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34383907</ArticleId><ArticleId IdType="pmc">PMC8433592</ArticleId><ArticleId IdType="doi">10.1093/jnen/nlab061</ArticleId><ArticleId IdType="pii">6349209</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ravits J, Appel S, Baloh RH, et al.Deciphering amyotrophic lateral sclerosis: What phenotype, neuropathology and genetics are telling us about pathogenesis. Amyotroph Lateral Scler Frontotemporal Degener 2013;14(Suppl 1):5&#x2013;18</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3779649</ArticleId><ArticleId IdType="pubmed">23678876</ArticleId></ArticleIdList></Reference><Reference><Citation>Grad LI, Rouleau GA, Ravits J, et al.Clinical spectrum of amyotrophic lateral sclerosis (ALS). Cold Spring Harb Perspect Med 2017;7:a024117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5538408</ArticleId><ArticleId IdType="pubmed">28003278</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringholz GM, Appel SH, Bradshaw M, et al.Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology 2005;65:586&#x2013;90</Citation><ArticleIdList><ArticleId IdType="pubmed">16116120</ArticleId></ArticleIdList></Reference><Reference><Citation>Cykowski MD, Takei H, Schulz PE, et al.TDP-43 pathology in the basal forebrain and hypothalamus of patients with amyotrophic lateral sclerosis. Acta Neuropathol Commun 2014;2:171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4297460</ArticleId><ArticleId IdType="pubmed">25539830</ArticleId></ArticleIdList></Reference><Reference><Citation>Geser F, Brandmeir NJ, Kwong LK, et al.Evidence of multisystem disorder in whole-brain map of pathological TDP-43 in amyotrophic lateral sclerosis. Arch Neurol 2008;65:636&#x2013;41</Citation><ArticleIdList><ArticleId IdType="pubmed">18474740</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, et al.Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006;314:130&#x2013;3</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Bigio EH, Ince PG, et al.Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol 2007;61:427&#x2013;34</Citation><ArticleIdList><ArticleId IdType="pubmed">17469116</ArticleId></ArticleIdList></Reference><Reference><Citation>Turk M, Haaker G, Winter L, et al.C9ORF72-ALS: p62- and ubiquitin-aggregation pathology in skeletal muscle. Muscle Nerve 2014;50:454&#x2013;5</Citation><ArticleIdList><ArticleId IdType="pubmed">24817207</ArticleId></ArticleIdList></Reference><Reference><Citation>Cykowski MD, Powell SZ, Appel JW, et al.Phosphorylated TDP-43 (pTDP-43) aggregates in the axial skeletal muscle of patients with sporadic and familial amyotrophic lateral sclerosis. Acta Neuropathol Commun 2018;6:28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5899326</ArticleId><ArticleId IdType="pubmed">29653597</ArticleId></ArticleIdList></Reference><Reference><Citation>Onozato T, Nakahara A, Suzuki-Kouyama E, et al.Axonal TDP-43 aggregates in sporadic amyotrophic lateral sclerosis. Neuropathol Appl Neurobiol 2016;42:561&#x2013;72</Citation><ArticleIdList><ArticleId IdType="pubmed">26819002</ArticleId></ArticleIdList></Reference><Reference><Citation>Verstraete E, Kuiperij HB, van Blitterswijk MM, et al.TDP-43 plasma levels are higher in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2012;13:446&#x2013;51</Citation><ArticleIdList><ArticleId IdType="pubmed">22873561</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Del Tredici K, Toledo JB, et al.Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol 2013;74:20&#x2013;38</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3785076</ArticleId><ArticleId IdType="pubmed">23686809</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeuchi R, Tada M, Shiga A, et al.Heterogeneity of cerebral TDP-43 pathology in sporadic amyotrophic lateral sclerosis: Evidence for clinico-pathologic subtypes. Acta Neuropathol Commun 2016;4:61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4918136</ArticleId><ArticleId IdType="pubmed">27338935</ArticleId></ArticleIdList></Reference><Reference><Citation>Cykowski MD, Powell SZ, Peterson LE, et al.Clinical significance of TDP-43 neuropathology in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 2017;76:402&#x2013;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5901081</ArticleId><ArticleId IdType="pubmed">28521037</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper-Knock J, Hewitt C, Highley JR, et al.Clinico-pathological features in amyotrophic lateral sclerosis with expansions in C9ORF72. Brain 2012;135:751&#x2013;64</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3286332</ArticleId><ArticleId IdType="pubmed">22366792</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymenidou M, Cleveland DW.. The seeds of neurodegeneration: Prion-like spreading in ALS. Cell 2011;147:498&#x2013;508</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220614</ArticleId><ArticleId IdType="pubmed">22036560</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravits J.Focality, stochasticity and neuroanatomic propagation in ALS pathogenesis. Exp Neurol 2014;262 Pt B:121&#x2013;6</Citation><ArticleIdList><ArticleId IdType="pubmed">25108067</ArticleId></ArticleIdList></Reference><Reference><Citation>Piotrkiewicz M, Hausmanowa-Petrusewicz I.. Amyotrophic lateral sclerosis: A dying motor unit? Front Aging Neurosci 2013;5:7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3607785</ArticleId><ArticleId IdType="pubmed">23533375</ArticleId></ArticleIdList></Reference><Reference><Citation>Fatima M, Tan R, Halliday GM, et al.Spread of pathology in amyotrophic lateral sclerosis: Assessment of phosphorylated TDP-43 along axonal pathways. Acta Neuropathol Commun 2015;3:47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4517552</ArticleId><ArticleId IdType="pubmed">26216351</ArticleId></ArticleIdList></Reference><Reference><Citation>Bobinski M, Wegiel J, Tarnawski M, et al.Relationships between regional neuronal loss and neurofibrillary changes in the hippocampal formation and duration and severity of Alzheimer disease. J Neuropathol Exp Neurol 1997;56:414&#x2013;20</Citation><ArticleIdList><ArticleId IdType="pubmed">9100672</ArticleId></ArticleIdList></Reference><Reference><Citation>Cykowski MD, Coon EA, Powell SZ, et al.Expanding the spectrum of neuronal pathology in multiple system atrophy. Brain 2015;138:2293&#x2013;309</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4840945</ArticleId><ArticleId IdType="pubmed">25981961</ArticleId></ArticleIdList></Reference><Reference><Citation>Geser F, Martinez-Lage M, Robinson J, et al.Clinical and pathological continuum of multisystem TDP-43 proteinopathies. Arch Neurol 2009;66:180&#x2013;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2774117</ArticleId><ArticleId IdType="pubmed">19204154</ArticleId></ArticleIdList></Reference><Reference><Citation>Majumder V, Gregory JM, Barria MA, et al.TDP-43 as a potential biomarker for amyotrophic lateral sclerosis: A systematic review and meta-analysis. BMC Neurol 2018;18:90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6027783</ArticleId><ArticleId IdType="pubmed">29954341</ArticleId></ArticleIdList></Reference><Reference><Citation>Haverkamp LJ, Appel V, Appel SH.. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain 1995;118:707&#x2013;19</Citation><ArticleIdList><ArticleId IdType="pubmed">7600088</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandmeir NJ, Geser F, Kwong LK, et al.Severe subcortical TDP-43 pathology in sporadic frontotemporal lobar degeneration with motor neuron disease. Acta Neuropathol 2008;115:123&#x2013;31</Citation><ArticleIdList><ArticleId IdType="pubmed">18004574</ArticleId></ArticleIdList></Reference><Reference><Citation>Cykowski MD, Dickson DW, Powell SZ, et al.Dipeptide repeat (DPR) pathology in the skeletal muscle of ALS patients with C9ORF72 repeat expansion. Acta Neuropathol 2019;138:667&#x2013;70</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6778061</ArticleId><ArticleId IdType="pubmed">31375896</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider CA, Rasband WS, Eliceiri KW.. NIH Image to ImageJ: 25 years of image analysis. Nat Methods 2012;9:671&#x2013;5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5554542</ArticleId><ArticleId IdType="pubmed">22930834</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen EC.Quantitative analysis of histological staining and fluorescence using ImageJ. Anat Rec (Hoboken) 2013;296:378&#x2013;81</Citation><ArticleIdList><ArticleId IdType="pubmed">23382140</ArticleId></ArticleIdList></Reference><Reference><Citation>R: A Language and Environment for Statistical Computing. [Computer Program]. Vienna, Austria 2021</Citation></Reference><Reference><Citation>Appel SH, Zhao W, Beers DR, et al.The microglial-motoneuron dialogue in ALS. Acta Myol 2011;30:4&#x2013;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3185827</ArticleId><ArticleId IdType="pubmed">21842586</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamanaka K, Chun SJ, Boillee S, et al.Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci 2008;11:251&#x2013;3</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3137510</ArticleId><ArticleId IdType="pubmed">18246065</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P, Deng J, Dong J, et al.TDP-43 induces mitochondrial damage and activates the mitochondrial unfolded protein response. PLoS Genet 2019;15:e1007947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6524796</ArticleId><ArticleId IdType="pubmed">31100073</ArticleId></ArticleIdList></Reference><Reference><Citation>McAlary L, Plotkin SS, Yerbury JJ, et al.Prion-like propagation of protein misfolding and aggregation in amyotrophic lateral sclerosis. Front Mol Neurosci 2019;12:262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6838634</ArticleId><ArticleId IdType="pubmed">31736708</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishihira Y, Tan CF, Hoshi Y, et al.Sporadic amyotrophic lateral sclerosis of long duration is associated with relatively mild TDP-43 pathology. Acta Neuropathol 2009;117:45&#x2013;53</Citation><ArticleIdList><ArticleId IdType="pubmed">18923836</ArticleId></ArticleIdList></Reference><Reference><Citation>Spencer KR, Foster ZW, Rauf NA, et al.Neuropathological profile of long-duration amyotrophic lateral sclerosis in military Veterans. Brain Pathol 2020;30:1028&#x2013;40</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8018169</ArticleId><ArticleId IdType="pubmed">32633852</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EB, Porta S, Michael Baer G, et al.Expansion of the classification of FTLD-TDP: Distinct pathology associated with rapidly progressive frontotemporal degeneration. Acta Neuropathol 2017;134:65&#x2013;78</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5521959</ArticleId><ArticleId IdType="pubmed">28130640</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan JA, Hudson AJ.. Changes in sizes of cortical and lower motor neurons in amyotrophic lateral sclerosis. Brain 1991;114:843&#x2013;53</Citation><ArticleIdList><ArticleId IdType="pubmed">2043953</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawyer T Jr, Netsky MG.. Amyotrophic lateral sclerosis. AMA Arch Neurol Psychiatry 1953;69:171&#x2013;92</Citation><ArticleIdList><ArticleId IdType="pubmed">13007227</ArticleId></ArticleIdList></Reference><Reference><Citation>Pamphlett R, Kril J, Hng TM.. Motor neuron disease: A primary disorder of corticomotoneurons? Muscle Nerve 1995;18:314&#x2013;8</Citation><ArticleIdList><ArticleId IdType="pubmed">7870109</ArticleId></ArticleIdList></Reference><Reference><Citation>Udaka F, Kameyama M, Tomonaga M.. Degeneration of Betz cells in motor neuron disease. A Golgi study. Acta Neuropathol 1986;70:289&#x2013;95</Citation><ArticleIdList><ArticleId IdType="pubmed">2429495</ArticleId></ArticleIdList></Reference><Reference><Citation>Soler-Martin C, Vilardosa U, Saldana-Ruiz S, et al.Loss of neurofilaments in the neuromuscular junction in a rat model of proximal axonopathy. Neuropathol Appl Neurobiol 2012;38:61&#x2013;71</Citation><ArticleIdList><ArticleId IdType="pubmed">21450050</ArticleId></ArticleIdList></Reference><Reference><Citation>Fallini C, Bassell GJ, Rossoll W.. The ALS disease protein TDP-43 is actively transported in motor neuron axons and regulates axon outgrowth. Hum Mol Genet 2012;21:3703&#x2013;18</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3406762</ArticleId><ArticleId IdType="pubmed">22641816</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne S, Elamin M, Bede P, et al.Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: A population-based cohort study. Lancet Neurol 2012;11:232&#x2013;40</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3315021</ArticleId><ArticleId IdType="pubmed">22305801</ArticleId></ArticleIdList></Reference><Reference><Citation>Umoh ME, Fournier C, Li Y, et al.Comparative analysis of C9orf72 and sporadic disease in an ALS clinic population. Neurology 2016;87:1024&#x2013;30</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5027809</ArticleId><ArticleId IdType="pubmed">27488601</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>